Denali Capital Acquisition CORP

Semnur Pharmaceuticals has signed a binding term sheet for a $100 million strategic investment from iHolding Group LLP to advance its pipeline, including the SEMDEXA Phase 3 program.

Semnur Pharmaceuticals, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of a director and the approval of key equity incentive plans.

Semnur Pharmaceuticals, Inc. announced the termination of two significant securities purchase agreements, one with JW Capital Securities Limited and another with Biconomy PTE. Ltd.

Semnur Pharmaceuticals, Inc. announced the retirement of its CEO and President, Jaisim Shah, and the appointment of Henry Ji, Ph.D., as the new CEO and President, and Stephen Ma as Chief Operating Officer.

Semnur Pharmaceuticals, Inc. filed an 8-K to update its securities description and corporate governance following its September 2025 business combination.

Semnur Pharmaceuticals, Inc. finalized its business combination, becoming a public entity and announcing a significant $100 million equity investment paid in Bitcoin.

Semnur Pharmaceuticals reported increased losses and negative cash flow for Q1 2026, raising substantial doubt about its going concern ability, while terminating two significant equity financing agreements.

Semnur Pharmaceuticals, Inc. reported significant operating losses and negative cash flows for Q3 2025, following its business combination and facing delays in anticipated capital raises.

Denali Capital Acquisition Corp. reports significant financial distress, including a going concern warning and Nasdaq delisting, as it pursues a merger with Semnur Pharmaceuticals.

Denali Capital Acquisition Corp. reports a net loss for the first quarter of 2025 and is addressing its Nasdaq delisting while pursuing a business combination with Semnur Pharmaceuticals.

Denali Capital Acquisition Corp. reported its financial results for the quarter ended September 30, 2024, while also detailing its ongoing efforts to secure a business combination and maintain its Nasdaq listing.

Denali Capital Acquisition Corp. reported a net income of $713,242 for the first six months of 2024, while navigating the complexities of finding a suitable business combination target.

Semnur Pharmaceuticals, a late-stage biopharmaceutical company, reported significant losses and a going concern doubt, while advancing its lead non-opioid pain candidate, SP-102, into a second Phase 3 trial.

Denali Capital Acquisition Corp.'s annual report reveals substantial doubt about its ability to continue as a going concern, despite efforts to merge with Semnur Pharmaceuticals.

Denali Capital Acquisition Corp.'s annual report outlines the company's financial status, progress on its merger with Longevity Biomedical, and ongoing efforts to meet Nasdaq listing requirements.

Scilex Holding Co. has distributed a stock dividend of Semnur Pharmaceuticals, Inc. common stock to its shareholders and holders of warrants and convertible notes.

Scilex Holding Co and Scilex, Inc. sold 12.5 million Semnur shares for $200 million, paid in Bitcoin.

Denali Capital Acquisition Corp. announced a $20 million private investment in public equity (PIPE) financing to support its planned business combination with Semnur Pharmaceuticals, Inc.

Denali Capital Acquisition Corp. extended its deadline to complete a business combination by one month to September 11, 2025, by depositing $874.78 into its Trust Account.

Denali Capital Acquisition Corp. has amended its merger agreement with Semnur Pharmaceuticals, Inc. to allow for the issuance of additional Semnur shares prior to closing, primarily for potential private placement financing and advisor compensation.

Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month to August 11, 2025, through a $874.78 deposit into its Trust Account.

Semnur Pharmaceuticals, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 25, 2026.

Denali Capital Acquisition Corp. has secured a $20 million private investment in public equity (PIPE) financing from JW Capital Securities Limited to support its merger with Semnur Pharmaceuticals, Inc.

Denali Capital Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination from April 11, 2025, to December 11, 2025, to allow more time to finalize a deal.

Denali Capital Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination to April 11, 2025, after terminating its merger agreement with Longevity Biomedical, Inc.

Semnur Pharmaceuticals files an S-1/A registration statement detailing its recent business combination, ongoing clinical development for its lead non-opioid pain candidate SP-102, and significant financial losses.

Semnur Pharmaceuticals filed an S-1 registration statement, outlining its non-opioid pain product SP-102's development, recent business combination, and significant financial challenges including a going concern doubt.

Scilex Holding Company reports a dividend distribution of Semnur Pharmaceuticals common stock to its shareholders.

Scilex Holding Company filed an amended Schedule 13D for Semnur Pharmaceuticals, Inc. to correct a previous filing error and detail its significant beneficial ownership and control following a recent business combination.

Meteora Capital, LLC and Vik Mittal have filed an amended Schedule 13G, reporting 0% beneficial ownership in Denali Capital Acquisition Corp.'s Class A common stock.

TD Bank Group entities filed an amended Schedule 13G for Denali Capital Acquisition Corp., reporting zero beneficial ownership of Class A ordinary shares.

Meteora Capital, LLC and its Managing Member, Vik Mittal, have filed an amended Schedule 13G, reporting zero beneficial ownership of Class A common stock in Denali Capital Acquisition Corp. as of May 31, 2025.

Meteora Capital, LLC and its Managing Member, Vik Mittal, have filed an amended Schedule 13G, reporting a continued beneficial ownership of 38.84% of Denali Capital Acquisition Corp.'s Class A common stock as of March 31, 2025.

Meteora Capital, LLC and its managing member Vik Mittal have reported a substantial increase in their beneficial ownership of Denali Capital Acquisition Corp.'s Class A ordinary shares to 39.53%, primarily driven by a significant redemption of shares by other public shareholders.